Omp - olfactory marker protein Gene

Species: Mus musculus

Gene Type: protein coding
Gene ID: 18378

Summary

Predicted to enable peptide binding activity. Acts upstream of or within neurogenesis and sensory perception of smell. Located in several cellular components, including axon; cytosol; and neuronal cell body. Is expressed in several structures, including brain; eye; genitourinary system; intestine; and olfactory system. Orthologous to human OMP (olfactory marker protein). [provided by Alliance of Genome Resources, Apr 2022]

Omp Products (1)

mRNA Protein Name
NM_011010.2 NP_035140.1 olfactory marker protein

Gene Ontology

  • Biological Process
  • Cellular Component
Biological Process GO Annotation Evidence Verweise Source
acts upstream of or within neurogenesis IDA
IDA: Inferred from direct assay
18184563 MGI
acts upstream of or within sensory perception of smell IMP
IMP: Inferred from mutant phenotype
10094125 MGI
Cellular Component GO Annotation Evidence Verweise Source
located in axon IDA
IDA: Inferred from direct assay
16052496 MGI
located in cytoplasm IDA
IDA: Inferred from direct assay
12911636 MGI
located in cytosol IDA
IDA: Inferred from direct assay
16805845 MGI
located in neuronal cell body IDA
IDA: Inferred from direct assay
16805845 MGI
located in nucleus IDA
IDA: Inferred from direct assay
12911636 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

olfactory marker protein

Omp Antibodies

Art. -Nr. Produktname Anwendung Reactivity
HY-P81729 Olfactory Marker Protein Antibody (YA1474) WB, IP Mouse, Rat
HY-P81729A Olfactory Marker Protein Antibody (YA1474)(PBS only) WB, IP Mouse, Rat

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Inhibitory Antibodies (7)
Art. -Nr. Produktname Wirkung
Reinheit Phase
HY-P99377 Navicixizumab Inhibitor 99.83% Phase 3
HY-P99320 Tarextumab Inhibitor 99.83% Phase 2
HY-P99261 Demcizumab Inhibitor 99.37% Phase 2
HY-P9974 Vantictumab Inhibitor 99.40% Phase 1
HY-P99401 Rosmantuzumab Inhibitor 99.29% Phase 1
HY-P99258 Brontictuzumab Inhibitor 95.00% Phase 1
HY-P99667 Ipafricept Inhibitor 99.80% Phase 1

Pre-clinical Phase

Bioactive Molecules (7)
Art. -Nr. Produktname
Wirkung
Reinheit
Rare Diseases
HY-146412 Vanin-1-IN-3 Inhibitor 96.20% Unkown
HY-E71014 Orotidine-5'-monophosphate pyrophosphorylase, Brewer's bottom yeast / Unkown
HY-RS09784 OMP Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-162672 Antibacterial agent 231 Inhibitor / Unkown
HY-RS16985 Omp Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23428 Omp Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W826156A 6-Aza-UMP disodium Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Omp NCBI NCBI:4975